Lisa Kroon, PharmD, CDCES, FAPhA
Dr. Lisa Kroon is a Professor of Clinical Pharmacy in the Department of Clinical Pharmacy at the School of Pharmacy at the University of California in San Francisco. She is also the Assistant Chief Pharmacy Office of Clinical Innovation, Education and Research at UCSF Health and oversees ambulatory pharmacy practice. Dr. Kroon received her Doctor of Pharmacy at the University of Michigan and then completed two years of residency at UCSF in pharmacy practice and hospital pharmacy administration. She has been a member of the UCSF faculty since 1996. She practices at the UCSF Health Diabetes Teaching Center, where she cares for people with diabetes. Dr. Kroon is the Co-Director of the UCSF Health Fontana Tobacco Treatment Center where she has been a smoking cessation provider for over 20 years. Her current research interests include evaluating the impact of pharmacist provider status and expanded scope of practice, diabetes therapeutics, tobacco cessation, and innovative pharmacy practice models.
Deirdra Stockmann, Ph.D., M.U.P. is the Director of the Division of Quality and Health Outcomes in the Center for Medicaid and CHIP Services at the Centers for Medicare & Medicaid Services (CMS). Since joining CMS in 2012, Deirdra has worked with state Medicaid and CHIP agencies and their partners to improve health outcomes by improving access to and quality of health services for people enrolled in Medicaid and CHIP. Before joining CMS, Deirdra worked on multi-stakeholder collaborations to address social determinants of health and other aspects of community wellbeing. Deirdra holds a Ph.D. and Masters in Urban Planning from the University of Michigan and a Bachelors from the University of Pennsylvania.
Ivana Thompson earned her Pharm.D. degree from University of the Pacific School of Pharmacy and has been practicing in California for over 20 years. She has worked in community and outpatient pharmacies, then as a consultant pharmacist for Medi-Cal DUR. Ivana took a leadership position managing Medicaid pharmacy operations with PBM overseeing 24+ Medicaid Managed Care plans from 20+ states. She is currently the Chief of pharmacy Clinical Operations Section, at California Department of Healthcare Services, where she oversees Medi-Cal Rx, a statewide Medicaid pharmacy benefit, and is responsible for Medi-Cal DUR Program.
- Describe how state Medicaid and CHIP agencies are working with health departments and health plans to improve delivery of tobacco cessation services to Medicaid and CHIP beneficiaries.
- Describe two pharmacist care models for smoking cessation in California.
- List the smoking cessation medications that pharmacists are able to furnish in California.
- Explain the power of how contracting with Medicaid or Medicaid MCOs can improve the delivery of tobacco treatment in health and behavioral healthcare settings
- Describe critical contracting elements to ensure successful implementation of tobacco treatment integration.
The CME/CE registration site has closed for this live activity. Credit will be available again for the recorded version of this webinar in December.
Certificates of Attendance
Click here to generate a certificate of attendance for participating on this webinar.
ACCME Accreditation
In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
UCSF designates this live activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.
Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.
Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.
California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA category 1 CreditTM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.
California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditTM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.
APA: Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
Up to 1.25 CE Credit may be claimed.
ASWB: As a Jointly Accredited Organization, UCSF Continuing Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 general continuing education credit.
Interprofessional Continuing Education Credit (IPCE): This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosures
This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Catherine Bonniot, Christine Cheng, Brian Clark, Lisa Kroon, PharmD, CDCES, FAPhA, Jennifer Matekuare, Ma Krisanta Pamatmat, MPH, CHES, Jessica Safier, MA, Jason Satterfield, PhD, Deirdre Stockmann, PhD, Joyce Swetlick, MPH, Ivana Thompson, PharmD, and Maya Vijayaraghavan, MD, MAS.